The Italian Family That Just Spent $4.1 Billion to Break Into America

Catalyst also owns U.S. rights to Fycompa, an epilepsy drug picked up from Eisai. Combined, the three products drove $589 million in total company revenue in 2025, growing nearly 20% year over year. The 2026 guidance sits at $615 to $645 million.

The $31.50 Question

Angelini is paying $31.50 per share, all cash. That represents a 21% premium to Catalyst's closing price on April 22 (the last "unaffected" trading day before deal rumors started swirling) and a 28% premium to the 30-day average.

Sounds generous, right? Well, it depends on who you ask.

At roughly 6.5 times Catalyst's 2026 expected revenue, analysts describe the price as full but not absurd. One common framing: Angelini isn't paying for a pipeline. It's paying for a machine. Patient identification systems, specialty pharmacy relationships, reimbursement expertise, physician networks. The entire infrastructure needed to sell rare disease drugs in the United States.

Building that from scratch would take a decade and hundreds of millions of dollars. Buying Catalyst gets Angelini there overnight.

The Platform Play (and Its Risks)

This deal only makes sense if you think of it as chapter one, not the whole book.

Analysts are calling it a "platform buy." The idea is straightforward: Angelini now owns a U.S. rare disease commercial engine. Future drugs, whether developed internally or acquired, can be plugged directly into Catalyst's sales force and market access team. Each additional product becomes cheaper to launch because the infrastructure already exists.

Angelini has been building toward this for years. It bought Arvelle Therapeutics in 2021 for up to $960 million, gaining an epilepsy drug called Ontozry in Europe. It invested in GRIN Therapeutics for rare pediatric epilepsy assets. It signed deals with JCR Pharmaceuticals and Cureverse for next-generation brain health therapies.

The Catalyst acquisition ties all of those threads together into a coherent global story: brain health and rare neurological disease, from Europe to the U.S.

But the risk is real. Firdapse alone accounts for more than 60% of Catalyst's revenue. If anything disrupts that franchise (generic competition eventually, payer pushback, or regulatory changes), the math gets uncomfortable fast. And with limited internal pipeline, Angelini will need to keep doing deals to justify what it paid. As one analyst put it: "The platform thesis only works if future assets follow. Angelini is now on a tighter track."

Part of a Bigger Wave

Angelini isn't the only mid-sized European pharma writing big checks in America. Just weeks before this deal, Italy's Chiesi Group agreed to acquire KalVista Pharmaceuticals, a U.S. company focused on hereditary angioedema (another rare disease), for roughly $1.9 billion.

The pattern is clear. Mid-sized European pharma companies are flush with cash but growth-constrained at home. The U.S. has the richest innovation pipeline, the most favorable orphan drug economics, and the pricing power that rare disease drugs need to thrive. So European buyers are going shopping.

Think of it like European soccer clubs buying South American talent: go where the best assets are, bring them into your system, and build something bigger than either side could manage alone.

What Happens Next

Both boards have unanimously approved the deal. Closing is expected in Q3 2026, pending Catalyst shareholder approval and standard regulatory clearances. Angelini plans to fund it with a mix of cash on hand and debt.

For Catalyst shareholders, this is a clean exit at a solid premium. At least one analyst downgraded the stock to "Perform" after the announcement, essentially saying: the upside is already baked in at $31.50, so there's no point chasing it further.

For Angelini, the real work starts after close. The family-owned company, now over a hundred years old, just made the most consequential bet in its history. It bought a ready-made rare disease business in the world's largest pharmaceutical market.

Now it has to prove it can run one.

Bayer Just Wrote a $2.45B Check for an Eye Drug You've Never Heard Of

Bayer is paying up to $2.45 billion for a tiny biotech that raised just $11 million in venture funding. The target: a glaucoma implant that doesn't lower eye pressure at all, but might be the first drug to actually reverse the damage.